Publication | Closed Access

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

First-line TherapyBreast OncologyMedicinePharmacologyClinical TrialsBreast CancerPharmacotherapyCancer TreatmentOncology